Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 11/03/25
Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the StockThe Motley Fool • 11/03/25
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant GliomaBusiness Wire • 10/23/25
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025Business Wire • 10/20/25
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung CancerBusiness Wire • 09/30/25
Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung CancerBusiness Wire • 09/19/25
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung CancerBusiness Wire • 09/07/25
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 08/27/25
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 08/07/25
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual CongressesBusiness Wire • 08/05/25
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025Business Wire • 07/24/25
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to BuyZacks Investment Research • 07/09/25
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung CancersBusiness Wire • 06/24/25
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.GlobeNewsWire • 06/16/25
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung CancerBusiness Wire • 06/11/25
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual MeetingBusiness Wire • 05/21/25